Navigation Links
Novogen Appoints Iain Ross as Acting CEO and Re-appoints Him to the Board
Date:7/22/2015

SYDNEY, July 22, 2015 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ: NVGN), a US-Australian drug development company, today announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made.

Mr Ross is currently Chairman of Premier Veterinary Group PLC (formerly Ark Therapeutics PLC), a non-executive director of Amarantus Bioscience Holdings Inc and a non-executive director for ASX-listed companies Anatara Lifesciences Ltd, Benitec Biopharma Ltd and Tissue Therapies Ltd.

Following a career with multinational companies, Sandoz AG, Hoffman La Roche and Celltech Group plc, Mr Ross has over the past 20 years undertaken a number of company start-ups, turnarounds and exits as a Board member on behalf of private equity groups and banks. These include Quadrant Healthcare PLC (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia AB (sold to Cinven); SR Pharma PLC (merged with Atugen AG to form Silence Therapeutics PLC) Allergy Therapeutics Limited (prepared for IPO); and Ark Therapeutics PLC (subsidiaries sold off to private equity and a new business reversed in to form Premier Veterinary Group PLC).

Mr Ross brings to this role an impressive track record which includes multiple financing transactions, having raised more than GBP250m, both publicly and privately, as well as extensive experience in divestments and strategic restructures and more than 20 years in cross border management as a Chairman and CEO. He has led and participated in five IPOs on the London and Australian Stock Exchanges and two up-listings to NASDAQ, and has direct experience of M&A transactions in Europe, the US and Pacific Rim. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University.

Iain Ross said he was extremely pleased to be able to re-join the Board of Novogen at a time when the Company is making great progress on all fronts.

"The management team is extremely capable and experienced and I look forward to working again in particular with Dr Andrew Heaton, who was responsible for the discovery of the super-benzopyran technology platform, Dr Justine Stehn, who along with Professor Peter Gunning are responsible for out anti-tropomyosin assets and the Company's CSO Dr David Brown," Mr Ross said.

"Novogen has an outstanding team of scientists, a strong management group and an experienced and committed Board of Directors. My goal in the short term is to bring focus and clarity to the organisation, whilst finding the best person to lead the Company going forward. We intend to keep shareholders fully informed during this transition."

Interim Chairman, Ian Phillips, added, "I am pleased we have been able to persuade Iain to re-join the Novogen Board and that he has agreed to take on the role of Acting CEO. We have initiated a worldwide search for a permanent appointment."

About Novogen

Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms (the super-benzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that are first-in-class with potential application across a range of cancers. Given the encouraging data from in vitro and in vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to bring our lead Oncology drug candidates Cantrixil, Anisina and Trilexium into the clinic in 2016 pending successful completion of their respective toxicology programs. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to therapy.

For more information, please visit www.novogen.com.



'/>"/>
SOURCE Novogen Ltd
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy
2. Novogen Announces Results of General Meeting of Shareholders
3. Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
4. Novogen Investor Briefing Well Received
5. Novogen Announces the Chairmans Address at the Companys General Meeting
6. Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors
7. Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors
8. Smart Insurance Company Appoints John Gardynik CEO
9. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
10. Kite Pharma Appoints Keith Nolop, M.D. Chief Medical Officer
11. Sinovac Appoints New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... March 20, 2019 , ... Latitude is the new ... administration firm specializing in quality retirement plan administration, Latitude has offices nationally and ... is as much an idea as it is a destination. It reflects our ...
(Date:3/20/2019)... ... March 20, 2019 , ... Dr. Jason Tucker founded ... stem cells for treating acute and chronic injuries such as arthritis, joint, ligament and ... a wide range of patients from NBA & NFL athletes to weekend warriors to ...
(Date:3/20/2019)... N.J. (PRWEB) , ... March 20, 2019 , ... ... that Greek American Rehabilitation & Care Centre used its SmartLinx suite to refute ... Services (CMS) regulations. , When the Illinois Department of Public Health regulators alleged ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... ... Vera Whole Health , a national leader in advanced primary care, ... employees healthy and drive down the total cost of care. This white paper is ... clinics. , The Vera white paper covers several topics including:, ...
(Date:3/20/2019)... ... March 20, 2019 , ... Dr. Joe Lowrance, psychologist ... for financial consultants: “Learn to practice mindfulness.” , In a white paper, ... Dr. Lowrance writes that financial advisors are discovering the power of mindfulness as ...
(Date:3/20/2019)... ... March 20, 2019 , ... ... today the launch of its mSource® Predictive Plan, a new analytics feature that ... It gives purchased services teams the control to develop a customized purchasing roadmap ...
(Date:3/20/2019)... ... March 20, 2019 , ... Nike Softball Camp ... Slupinski will be leading the camp with her staff. , Coach Slupinski takes the ... Redlands where she was the head coach for 2 seasons. Slupinski had an impressive ...
(Date:3/20/2019)... ... , ... Dr. Samuel Lin, board-certified Nose Expert representing the ... Network, well known for their exclusivity, and luxurious lifestyle is privileged to present ... to the Haute Living partnership. , Haute Beauty offers a prominent collective of ...
Breaking Medicine News(10 mins):